Your session is about to expire
← Back to Search
Antifibrinolytic
TXA (1g) for Postpartum Hemorrhage (TAPPH-1 Trial)
Phase 2
Waitlist Available
Led By Asim Q Alam, MD, FRCPC
Research Sponsored by Sunnybrook Health Sciences Centre
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 4 months
Awards & highlights
Summary
This study is evaluating whether a drug called tranexamic acid can prevent postpartum hemorrhage.
Eligible Conditions
- Postpartum Hemorrhage
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 4 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 4 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Number of patients receiving study intervention
Secondary outcome measures
Composite number of clinical events
Duration of study to recruit 58 participants
Incidence of PPH in study participants
+1 moreTrial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: TXA (1g)Experimental Treatment1 Intervention
For vaginal, TXA (1g) will be administered upon delivery of the anterior shoulder. For c-section, TXA (1g) will be administered when the obstetrician begins to cleanse the incision site
Group II: Placebo (0.9% saline)Placebo Group1 Intervention
For vaginal, placebo (0.9% saline) will be administered upon delivery of the anterior shoulder. For c-section, placebo (0.9% saline) will be administered when the obstetrician begins to cleanse the incision site
Find a Location
Who is running the clinical trial?
Sunnybrook Health Sciences CentreLead Sponsor
661 Previous Clinical Trials
1,554,020 Total Patients Enrolled
Asim Q Alam, MD, FRCPCPrincipal InvestigatorSunnybrook Health Sciences Centre
Stephen Choi, MD,FRCPC,MScPrincipal InvestigatorSunnybrook Health Sciences Centre
3 Previous Clinical Trials
777 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger